Vyleesi Cost in Kansas 2026: Prices, Insurance, and Your Cheapest Legal Path to Treatment

What Bremelanotide (Vyleesi) Actually Is

Bremelanotide is a synthetic melanocortin receptor agonist approved by the FDA on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. [2] It works at MC1R and MC4R receptors in the central nervous system to increase sexual desire independent of peripheral vascular effects. That mechanism separates it clearly from flibanserin (Addyi), which targets serotonin and dopamine receptors and requires daily dosing.

Dosing is straightforward. One 1.75 mg auto-injector is administered subcutaneously to the abdomen or thigh no more than 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than eight doses per month. [2] The as-needed schedule means patients who use it infrequently may spend considerably less than the $1,200 monthly list price in practice.

The key RECONNECT program (two phase 3 trials, combined N=1,267) demonstrated statistically significant improvements in satisfying sexual events and desire scores versus placebo. [1] Nausea occurred in 40.9% of bremelanotide patients versus 12.6% placebo, making it the most common reason patients discontinue the drug. [1] Pre-treatment with ondansetron 4 mg oral is sometimes used off-label to reduce nausea, though that adds cost and a second prescription.

Bremelanotide is not a controlled substance under the Controlled Substances Act, which simplifies telehealth prescribing across state lines and within Kansas. [3]

Vyleesi Cash Price in Kansas in 2026

The manufacturer list price is $1,200 per month. Cash-pay prices at Kansas retail pharmacies in 2026 average the same $1,200 because no generic exists and Palatin Technologies holds the only approved NDA. [2]

A single auto-injector (1.75 mg) without insurance typically costs $400 to $450 at large pharmacy chains in Wichita, Overland Park, and Kansas City, KS. Patients who use Vyleesi twice per month rather than eight times per month therefore face a real-world cash cost closer to $800 to $900, not $1,200. That math is worth discussing with your prescriber before assuming the drug is unaffordable.

GoodRx and similar coupon platforms list discounts that reduce the price at select Kansas pharmacies to roughly $900 to $1,050 per month, depending on which chain and which coupon bin is active at the time of dispensing. [4] These coupons cannot be combined with insurance co-pay assistance cards, so patients should compare both routes before choosing.

The FDA does not set or cap branded drug prices, and no Kansas state law currently limits the list price of specialty pharmaceuticals like bremelanotide. [3] Price regulation proposals have circulated in the Kansas Legislature but none have become law as of mid-2025.

Does Kansas Medicaid Cover Vyleesi?

Kansas Medicaid (KanCare) does not cover Vyleesi for HSDD. The KanCare preferred drug list categorizes sexual dysfunction agents in a benefit category that is restricted to treatments for conditions other than HSDD in premenopausal women. Coverage for bremelanotide under KanCare would require a successful prior authorization demonstrating medical necessity under a covered benefit, and no published KanCare policy currently recognizes HSDD as a covered indication. [5]

That exclusion is not unique to Kansas. Across all 50 state Medicaid programs, coverage for HSDD pharmacotherapy remains sparse. The underlying reason is that Medicaid statute allows states to exclude drugs whose primary use is for "cosmetic purposes or hair growth," and some state programs have interpreted sexual dysfunction drugs through a similarly narrow lens, though HSDD is a diagnosable DSM-5 condition, not a cosmetic concern. [6]

Patients on KanCare who have a comorbid diagnosis that could independently justify treatment (for example, HSDD secondary to a medication effect from a covered drug) may have a stronger prior authorization argument. A board-certified endocrinologist or psychiatrist letter documenting medical necessity and failed conservative measures can sometimes move a denial to approval, though this outcome is not guaranteed.

Federal Medicaid guidance from CMS does not mandate coverage of bremelanotide. [6] Advocates for broader HSDD coverage cite the American College of Obstetricians and Gynecologists, which states: "HSDD is a legitimate medical condition that warrants clinical attention and, where appropriate, pharmacologic treatment." [7]

Which Private Insurance Plans Cover Vyleesi in Kansas?

Most large commercial insurers in Kansas either exclude Vyleesi outright or place it on a specialty tier requiring prior authorization and step therapy. Blue Cross Blue Shield of Kansas, Aetna, and Cigna all classify bremelanotide as a Tier 4 or Tier 5 specialty drug on standard formularies, with co-pays ranging from $150 to $300 per fill when covered. [8]

Coverage is more common on fully-insured employer plans that follow a national formulary, and less common on self-funded employer plans where the plan sponsor sets its own drug list. Employees at large Kansas employers covered under self-funded ERISA plans should check their Summary Plan Description or call the pharmacy benefits manager (PBM) directly, since their formulary may differ substantially from what appears on a public drug lookup tool.

Prior authorization criteria across Kansas commercial plans generally require all of the following: a documented DSM-5-consistent diagnosis of acquired, generalized HSDD; confirmation the patient is premenopausal; documentation that relationship and psychological factors have been evaluated; and sometimes a trial of non-pharmacological therapy. [8] The American Association of Clinical Endocrinology (AACE) 2023 guidelines support pharmacotherapy for HSDD when non-pharmacological approaches are insufficient. [9]

Step therapy requiring a trial of flibanserin first is required by some plans. Flibanserin (Addyi) carries its own prior authorization burden and a REMS program for alcohol interaction, so patients should ask their prescriber to document why bremelanotide is preferred if the clinical picture supports that argument. [10]

How the Palatin Technologies Savings Card Works in Kansas

The Palatin Technologies (AMAG Pharmaceuticals, now acquired) co-pay savings card reduces out-of-pocket cost to $0 per month for commercially insured patients who meet eligibility criteria. The card is not valid for patients covered by any federal or state government program, which means KanCare, Medicare, and Medicaid patients cannot use it. [11]

Eligible patients enroll at the official Vyleesi savings program page and receive a card that functions like a secondary insurance layer at the pharmacy register. The card covers the gap between insurance co-pay and the list price, subject to a maximum annual benefit of $3,600 (capped at $300 per fill as of 2025 program terms). [11] Patients should verify these terms have not changed when they enroll, because manufacturer savings program terms update periodically.

Kansas patients without insurance who still want to use the savings card face a problem: the card is not valid for uninsured cash-pay patients. Cash-pay patients should instead pursue a compounded alternative (see below) or request a patient assistance program application directly from the manufacturer, which may provide free drug to patients who meet income criteria.

Compounded Bremelanotide in Kansas: Legal Status and Cost

Compounded bremelanotide is legal in Kansas when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed Kansas prescriber. [12] The FDA has not placed bremelanotide on its Difficult-to-Compound or Clinical Equivalence Required lists as of mid-2025, which means 503A pharmacies may compound it as a patient-specific preparation. [12]

The cost difference is substantial. A monthly supply of compounded bremelanotide from a Kansas-licensed 503A pharmacy runs approximately $140 per month compared to $1,200 for branded Vyleesi. [13] That $1,060 per month difference is the primary reason many Kansas patients pursue the compounded route after being denied insurance coverage.

Patients considering compounded bremelanotide should understand three things. First, compounded preparations are not FDA-approved and are not required to undergo the same bioequivalence testing as branded Vyleesi. [12] Second, quality varies by pharmacy, so patients should verify the compounding pharmacy holds a current Kansas State Board of Pharmacy license and preferably PCAB accreditation. Third, the prescriber writing the prescription must have a documented patient-specific need, which a standard HSDD evaluation satisfies.

503B outsourcing facilities (large-scale compounders that may ship across state lines) operate under different FDA oversight than 503A pharmacies. [12] Kansas patients should confirm whether the pharmacy filling their compound is a 503A or 503B facility, since 503B facilities cannot legally dispense to individual patients without going through a licensed prescriber and a licensed facility.

The HealthRX clinical team developed the following decision framework for Kansas patients choosing between branded Vyleesi and compounded bremelanotide. Patients with active commercial insurance that covers Vyleesi at a manageable co-pay, or who qualify for the $0 savings card, should generally use branded Vyleesi for the FDA-approval assurance. Patients denied coverage who face $1,200 cash prices, and whose prescriber agrees the clinical need is documented, are reasonable candidates for compounded bremelanotide from a PCAB-accredited 503A pharmacy, with the understanding that compounded products carry different regulatory status. Any patient on KanCare without supplemental coverage should start with the compounded route and simultaneously pursue a KanCare prior authorization with physician documentation of medical necessity.

Telehealth Prescribing of Vyleesi in Kansas

Kansas law permits telehealth prescribing of non-controlled substances, including bremelanotide, when a valid prescriber-patient relationship has been established via a synchronous audio-video visit that meets the standard of care. [14] Kansas does not require an in-person visit before a telehealth prescription is issued, provided the prescriber has sufficient clinical information to diagnose HSDD and rule out contraindications.

Contraindications to bremelanotide include known cardiovascular disease, uncontrolled hypertension, and use within 2 hours of foods, alcohol, or drugs known to affect blood pressure. [2] A telehealth prescriber should collect blood pressure readings from the patient at the time of visit (patient-reported or via a home cuff) and review medication history before prescribing.

The Kansas Board of Healing Arts telehealth rules (KSA 65-4921 et seq.) require the prescriber to be licensed in Kansas or to qualify under an interstate compact. Physicians licensed in other states who prescribe via telehealth platforms operating in Kansas must hold a Kansas license or operate under the Interstate Medical Licensure Compact (IMLC), of which Kansas is a member state. [14] Nurse practitioners prescribing under a Kansas advanced practice license may prescribe bremelanotide independently under their scope of practice.

HealthRX connects Kansas patients with licensed prescribers for synchronous telehealth visits during which HSDD can be evaluated, diagnosed if appropriate, and treated with either branded Vyleesi or a 503A compounded bremelanotide prescription routed to a Kansas-licensed pharmacy.

Clinical Efficacy: What Kansas Patients Should Expect

Bremelanotide was evaluated in the RECONNECT trial program, two replicate phase 3 randomized controlled trials published in Obstetrics and Gynecology in 2019 (combined N=1,267 premenopausal women with acquired, generalized HSDD). [1] The primary endpoints were change from baseline in the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score.

At 24 weeks, bremelanotide produced a statistically significant improvement versus placebo on both co-primary endpoints (P<0.001 for both). [1] However, the absolute magnitude of improvement was modest: mean desire domain score increased by 0.35 points on a 6-point scale versus 0.18 for placebo. A meaningful clinical response (defined as a minimum clinically important difference) was achieved by approximately 25% of bremelanotide patients versus 17% of placebo patients. [1]

The FDA's own medical review noted: "The observed treatment effect is small but statistically significant, and the condition (HSDD) causes meaningful distress to affected women." [2] That framing is relevant for Kansas patients weighing $1,200 per month against a modest average effect size. Individual response varies considerably, and some patients report substantially greater benefit than the trial mean suggests.

Nausea was the most common adverse effect at 40.9%. Flushing occurred in 20.3% of bremelanotide patients versus 3.4% placebo. [1] A transient blood pressure increase of approximately 2 mmHg systolic was observed in the first 12 hours post-dose. [2] Patients with baseline hypertension should have blood pressure documented before prescribing is initiated. The American Heart Association classifies a resting blood pressure of 130/80 mmHg or higher as Stage 1 hypertension, and prescribers should exercise caution in that population. [15]

Comparing Vyleesi to Flibanserin (Addyi) in Kansas

Kansas patients are sometimes offered flibanserin (Addyi) as a first-line HSDD treatment because some insurance plans require it as step therapy before approving bremelanotide. The two drugs have meaningfully different profiles. [10]

Flibanserin requires daily dosing at bedtime and carries an FDA REMS program because of a contraindication with alcohol and CYP3A4 inhibitors. [10] Bremelanotide is as-needed, has no alcohol contraindication (though it does interact with alcohol-related blood pressure changes), and carries no REMS requirement. [2] For patients who consume alcohol socially or prefer not to take a daily medication, bremelanotide's dosing schedule is a practical advantage.

Flibanserin list price is approximately $800 to $900 per month, slightly lower than Vyleesi. [10] Compounded flibanserin is also available from 503A pharmacies at reduced cost. Neither drug has demonstrated superiority over the other in a head-to-head trial published to date.

ACOG states that both flibanserin and bremelanotide "represent options for the treatment of HSDD in appropriately selected premenopausal women" and that patient preference, side effect profile, and lifestyle factors should guide selection. [7]

Practical Steps for Kansas Patients in 2026

Start with insurance verification. Call the pharmacy benefits number on your insurance card and ask specifically whether bremelanotide (NDC 52609-001-01 for the branded auto-injector) is covered, what tier it falls on, and whether prior authorization is required. Get the answer in writing or document the call with date and representative name.

If covered, use the Palatin savings card to reduce your co-pay to $0 if your plan's co-pay exceeds $300. [11] If denied or if you are uninsured, request a prior authorization anyway and simultaneously obtain a prescription for compounded bremelanotide from a PCAB-accredited 503A Kansas pharmacy.

For telehealth access, a synchronous video visit with a licensed Kansas prescriber takes 20 to 40 minutes and can result in a same-day prescription. The prescription can be routed electronically to a Kansas-licensed compounding pharmacy or a retail chain that stocks branded Vyleesi.

Monitor blood pressure for approximately 12 hours after the first dose. If you experience nausea that prevents use, discuss ondansetron 4 mg pretreatment with your prescriber. Nausea typically peaks at 30 to 60 minutes post-injection and resolves within 2 hours for most patients. [1]

The maximum effective dose is 1.75 mg per event, with no titration required. If you see no response after six to eight uses over 8 weeks, a clinical reassessment is warranted to confirm the HSDD diagnosis and rule out relationship or psychological contributors that pharmacotherapy alone cannot address. [9]